Axon Enterprise (NASDAQ:AXON) Given New $825.00 Price Target at JMP Securities

Axon Enterprise (NASDAQ:AXON - Free Report) had its price target increased by JMP Securities from $725.00 to $825.00 in a research report sent to investors on Tuesday,Benzinga reports. JMP Securities currently has a market outperform rating on the biotechnology company's stock.

AXON has been the subject of a number of other reports. The Goldman Sachs Group lifted their price objective on Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a research report on Wednesday, May 14th. Bank of America boosted their target price on Axon Enterprise from $750.00 to $895.00 and gave the stock a "buy" rating in a research report on Wednesday, June 4th. Barclays boosted their target price on Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. JPMorgan Chase & Co. lifted their price objective on Axon Enterprise from $730.00 to $850.00 and gave the company an "overweight" rating in a report on Thursday, July 17th. Finally, Needham & Company LLC lifted their price objective on Axon Enterprise from $600.00 to $750.00 and gave the company a "buy" rating in a report on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $772.08.

Axon Enterprise Price Performance

Shares of NASDAQ:AXON traded up $4.04 during midday trading on Tuesday, reaching $709.26. The company's stock had a trading volume of 1,104,660 shares, compared to its average volume of 703,554. Axon Enterprise has a fifty-two week low of $279.02 and a fifty-two week high of $830.21. The company has a market capitalization of $55.22 billion, a P/E ratio of 171.32, a P/E/G ratio of 80.34 and a beta of 1.29. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.83 and a quick ratio of 2.62. The business's fifty day simple moving average is $764.16 and its 200-day simple moving average is $648.27.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. The firm had revenue of $603.63 million during the quarter, compared to analyst estimates of $585.67 million. Axon Enterprise had a return on equity of 5.81% and a net margin of 14.86%. The company's revenue was up 31.3% on a year-over-year basis. During the same period last year, the company earned $1.15 earnings per share. As a group, equities research analysts expect that Axon Enterprise will post 5.8 EPS for the current fiscal year.

Insider Transactions at Axon Enterprise

In other news, CRO Cameron Brooks sold 3,000 shares of the company's stock in a transaction on Friday, May 30th. The stock was sold at an average price of $740.76, for a total transaction of $2,222,280.00. Following the completion of the sale, the executive directly owned 19,447 shares in the company, valued at approximately $14,405,559.72. This represents a 13.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Caitlin Elizabeth Kalinowski sold 1,300 shares of the company's stock in a transaction on Monday, May 19th. The shares were sold at an average price of $738.84, for a total value of $960,492.00. Following the sale, the director owned 4,829 shares of the company's stock, valued at approximately $3,567,858.36. The trade was a 21.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 34,642 shares of company stock worth $25,090,528. 4.40% of the stock is currently owned by company insiders.

Institutional Trading of Axon Enterprise

Several institutional investors and hedge funds have recently modified their holdings of AXON. Capital World Investors raised its position in Axon Enterprise by 86.4% in the fourth quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company's stock valued at $1,079,145,000 after purchasing an additional 841,772 shares during the last quarter. Alliancebernstein L.P. raised its position in Axon Enterprise by 273.8% in the fourth quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company's stock valued at $659,128,000 after purchasing an additional 812,337 shares during the last quarter. Norges Bank bought a new position in Axon Enterprise in the fourth quarter valued at about $482,081,000. GQG Partners LLC bought a new position in Axon Enterprise in the fourth quarter valued at about $478,349,000. Finally, GAMMA Investing LLC raised its position in Axon Enterprise by 58,725.5% in the first quarter. GAMMA Investing LLC now owns 764,731 shares of the biotechnology company's stock valued at $402,210,000 after purchasing an additional 763,431 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.